DIR Return Create A Forum - Home
---------------------------------------------------------
MS Speaks
HTML https://msspeaks.createaforum.com
---------------------------------------------------------
*****************************************************
DIR Return to: TREATMENTS
*****************************************************
#Post#: 1956--------------------------------------------------
Rituxan (rituximab)
By: agate Date: January 16, 2018, 4:02 pm
---------------------------------------------------------
From Multiple Sclerosis News Today, January 16, 2018--"Long-term
Rituxan Treatment Is Safe and Effective in MS, Study Shows":
HTML https://multiplesclerosisnewstoday.com/2018/01/16/study-shows-long-term-use-of-rituximab-is-safe-and-effective-for-ms/?utm_source=Multiple+Sclerosis&utm_campaign=58d203277a-RSS_US_EMAIL_CAMPAIGN&utm_medium=email&utm_term=0_b5fb7a3dae-58d203277a-71286581
#Post#: 2338--------------------------------------------------
Disability progression reduced among SPMS patients taking Rituxa
n
By: agate Date: January 7, 2019, 3:49 pm
---------------------------------------------------------
From JAMA Neurology (January 7, 2019)--this is a link to the
entire article, entitled "Association of rituximab treatment
with disability progression among patients with secondary
progressive multiple sclerosis":
HTML https://jamanetwork.com/journals/jamaneurology/fullarticle/2719699?guestAccessKey=17fb9684-d054-4bd4-a067-c9e3bb1b9462&utm_source=silverchair&utm_medium=email&utm_campaign=article_alert-jamaneurology&utm_content=olf&utm_term=010719
#Post#: 2343--------------------------------------------------
(Abst.) Rituximab vs. placebo induction prior to glatiramer acet
ate monotherapy in MS
By: agate Date: January 13, 2019, 7:30 pm
---------------------------------------------------------
This small study found that patients treated with rituximab
before switching to glatiramer acetate (Copaxone) were more
likely to show NEDA (no evidence of disease activity) than
patients who received placebo before the change to Copaxone.
From PubMed, January 13, 2019:
HTML https://www.ncbi.nlm.nih.gov/pubmed/30635477
Apparently the patients received 2 infusions of Rituxan before
starting daily Copaxone injections (from [font=source sans
pro]ClinicalTrials.gov Identifier: NCT01569451).[/font]
[quote]Active Comparator: (Placebo and) Glatiramer Acetate
Subjects will receive an intravenous (IV) infusion of placebo
(normal saline) on study days 1 (baseline visit) and 15
according to the infusion protocol. On study day 28, all
subjects will initiate standard Glatiramer Acetate therapy, 20
mg injected subcutaneously daily.
[font=sans-serif]Experimental: Rituximab and Glatiramer Acetate
(R-GA)
Subjects will receive an intravenous (IV) infusion of 1000 mg of
rituximab on study days 1 (baseline visit) and 15 according to
the rituximab infusion protocol. On study day 28, subjects will
initiate standard Glatiramer Acetate therapy, 20 mg injected
subcutaneously daily.[/font][/quote]
#Post#: 2565--------------------------------------------------
(Abst.) Rituximab treatment for MS
By: agate Date: June 27, 2019, 7:50 pm
---------------------------------------------------------
More in support of rituximab for treatment of both RRMS and
"progressive MS phenotypes," from PubMed (June 27, 2018):
HTML https://www.ncbi.nlm.nih.gov/pubmed/31237800
#Post#: 2629--------------------------------------------------
Aggressive MS in child dramatically resolved w/rituximab treatme
nt, case study reports
By: agate Date: August 25, 2019, 10:08 am
---------------------------------------------------------
From Multiple Sclerosis News Today (August 23,
2019)--"Aggressive MS in Child Dramatically Resolved with
Rituximab Treatment, Case Study Reports":
HTML http://bit.ly/2LdNgDM
#Post#: 2800--------------------------------------------------
(Abst.) Rituximab in MS at general hospital level
By: agate Date: February 2, 2020, 9:00 pm
---------------------------------------------------------
From PubMed, February 2, 2020--abstract of a Swedish study,
"Rituximab in multiple sclerosis at general hospital level":
HTML https://www.ncbi.nlm.nih.gov/pubmed/31990978
#Post#: 2820--------------------------------------------------
(Abst.) Rituximab in the treatment of MS in Southwest Finland
By: agate Date: February 22, 2020, 12:05 am
---------------------------------------------------------
From PubMed (February 20, 2020), "Rituximab in the treatment of
multiple sclerosis in the Hospital District of Southwest
Finland":
HTML https://www.ncbi.nlm.nih.gov/pubmed/32066031
#Post#: 2841--------------------------------------------------
Rituximab biosimilar could be $4 billion blockbuster
By: agate Date: March 12, 2020, 8:32 pm
---------------------------------------------------------
ABP798, a rituximab biosimilar, is about to be marketed--and is
expected to sell very well.
HTML https://pharmaphorum.com/news/amgen-allergans-rituximab-biosimilar-could-be-4bn-blockbuster/
#Post#: 2853--------------------------------------------------
(Abst.) Comparison of rituximab originator to biosimilar in pati
ents with MS
By: agate Date: March 24, 2020, 1:06 am
---------------------------------------------------------
From Multiple Sclerosis Journal (March 17, 2020)--"Comparison of
rituximab originator (MabThera) to biosimilar (Truxima) in
patients with multiple sclerosis":
HTML https://journals.sagepub.com/doi/abs/10.1177/1352458520912170
#Post#: 2991--------------------------------------------------
(Abst.) Rituxan vs. Tysabri, Gilenya, and Tecfidera in MS treatm
ent
By: agate Date: August 10, 2020, 11:13 am
---------------------------------------------------------
Some of the authors of the article abstracted here are well
known in MS research. From PubMed (August 10, 2020)--"Rituximab
versus natalizumab, fingolimod, and dimethyl fumarate in
multiple sclerosis treatment":
HTML https://pubmed.ncbi.nlm.nih.gov/32767538/
Note that clicking on the DOI in the abstract will take you to
the entire article.
There is also this--also indexed in PubMed (August 10) and with
some of the same authors--"Serious safety events in
rituximab-treated multiple sclerosis and related disorders":
HTML https://pubmed.ncbi.nlm.nih.gov/32767538/
*****************************************************
DIR Next Page